Abstract

Patients of the same cancer may differ in their responses to a specific medical therapy. Identification of predictive molecular features for drug sensitivity holds the key in the era of precision medicine. Human cell lines have harbored most of the same genetic changes found in patients’ tumors and thus are widely used in the research of drug response. In this work, we formulated drug-response prediction as a recommender system problem and then adopted a neighbor-based collaborative filtering with global effect removal (NCFGER) method to estimate anti-cancer drug responses of cell lines by integrating cell-line similarity networks and drug similarity networks based on the fact that similar cell lines and similar drugs exhibit similar responses. Specifically, we removed the global effect in the available responses and shrunk the similarity score for each cell line pair as well as each drug pair. We then used the K most similar neighbors (hybrid of cell-line-oriented and drug-oriented) in the available responses to predict the unknown ones. Through 10-fold cross-validation, this approach was shown to reach accurate and reproducible outcomes of drug sensitivity. We also discussed the biological outcomes based on the newly predicted response values.

Highlights

  • Cancer subtypes differ in chemotherapeutic response and may require different medical treatment

  • The other two recent consortiums, GDSC (Genomics of Drug Sensitivity in Cancer)[3] and CCLE (Cancer Cell Line Encyclopedia)[4] have analyzed around 1,500 cancer cell lines and their genomic profiles against 280 drugs, providing the concentration required for 50% of cellular growth inhibition (IC50) or activity area as drug-response measurement

  • The logIC50 values were split into quantiles, with cell lines in the first and fourth representing drug-sensitive (-resistant) and -resistant (-sensitive) cell lines, respectively, which followed the same definition in Wang et al.[17]

Read more

Summary

Introduction

Cancer subtypes differ in chemotherapeutic response and may require different medical treatment. The relationships between molecular features and clinical drug responses lay the foundation for optimizing drug therapies based on a patient’s genomic context.[1] it has been a major challenge to accurately predict the anti-cancer drug response based on the patient’s molecular and clinical profiles in the era of precision medicine. The emerging of high-throughput drugscreening technologies has enabled many studies to conduct large-scale experiments on cultured human cell line panels, which greatly improved systematical elucidation of the response mechanism of anti-cancer drugs. NCI-60 was a panel of human cell lines originally derived from human cancers spanning nine different tissues of origin.[2] The other two recent consortiums, GDSC (Genomics of Drug Sensitivity in Cancer)[3] and CCLE (Cancer Cell Line Encyclopedia)[4] have analyzed around 1,500 cancer cell lines and their genomic profiles against 280 drugs, providing the concentration required for 50% of cellular growth inhibition (IC50) or activity area as drug-response measurement. The sensitivity levels for most cell line-drug pairs are still unknown, and it needs to be achieved by a time- and cost-effective way for potential personalized medicine.[5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call